Revelation Biosciences Inc - REVB Enterprise Value-to-Revenue Multiple

revbiosciences.com (REVB) - corporate logo

Geopolitical barriers and sanctions are limiting international testing of immunological drugs from Revelation Biosciences (REVB). The enterprise value-to-revenue multiple visualizes the current market valuation, where the 0.00 indicator determines the parameter status. A lack of sales and reliance on equity offerings create financial risk, which is offset by a strong patent portfolio and development progress of the Gemini candidate for combating lung infections.

Revelation Biosciences, Inc. (REVB) - EV/Sales Multiple from 11/23/2025 to 11/20/2026

Revelation Biosciences Inc - analytical breakdowns and key metrics (REVB)

Fundamental valuation:Revelation Biosciences (REVB)
Flagship merchandise of Revelation Biosciences, Inc.

For Revelation Biosciences (REVB), this indicator reflects the enterprise value relative to generated revenue, which is critical when valuing a biotech company during the Gemini development stage and the protection of its patent portfolio. Analyzing the EV/Revenue multiple on the GURU.Markets platform allows for determining the extent of overpayment for future successes in renal failure therapy, identifying areas of undervaluation or the risk of capital freeze.

Competitor analysis for Revelation Biosciences

ARGX - EV/Sales Multiple|BNTX: EV/Sales Multiple|ABVX (Abivax SA) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio ADMA Corp|Enterprise Value-to-Revenue Multiple Protagonist Therapeutics PTGX|Company Value to Revenue IMVT (Immunovant Therapeutics)|Total Company Value-to-Revenue Ratio kiniksa.com|Enterprise Value-to-Revenue Ratio Grifols Biemat GRFS|Enterprise Value-to-Revenue Coefficient ADPT (Adaptive Biotechnologies Corporation)|celldex.com - EV/Sales Multiple|Total Company Value-to-Revenue Ratio Aurinia Pharma AUPH|biocryst.com (BCRX) - Enterprise Value-to-Revenue Ratio|Vera Therapeutics, Inc. - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Dianthus Therapeutics Inc|Pharvaris NV (PHVS) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple ABCL|Tourmaline Corp - Company Value to Revenue Ratio|EV/Sales Multiple PGEN (precigen.com)|Enterprise Value-to-Sales Ratio pharming.com|NKTR - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Upstream Bio Corp|ZBIO: EV/Sales Multiple|Company Value to Revenue Immunome, Inc.|Company Value to Revenue GOSS|KALV: Business Value to Revenue|EV/Sales Multiple SEPN|Company Value to Revenue Pieris Pharmaceuticals, Inc. PVLA|EV/Sales Multiple SVRA (Savara Inc)|EV/Sales Multiple Rigel Pharmaceuticals RIGL|AnaptysBio Inc. - EV/Sales Multiple|Astria Therapeutics - Enterprise Value-to-Revenue Coefficient|ENGN: EV/Sales Multiple|RAPT - Total Company Value-to-Revenue Ratio|Company Value to Revenue JBIO|Aclaris (ACRS) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple KYTX|Company Value to Revenue Tiziana Life Sciences TLSA|EV/Sales Multiple CABA (cabalettabio.com)|Enterprise Value-to-Revenue Coefficient VTYX (Ventyx Bio)|Theratechnologies, Inc - EV/Sales Multiple|AVTX (Avalo Therapeutics Inc.) - Company Value to Revenue Ratio|eledon.com (ELDN) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Ratio AGEN|CLYM (climbbio.com) - EV/Sales Multiple|EV/Sales Multiple zurabio.com|Enterprise Value-to-Revenue Ratio aTyr (ATYR)|ADAG - Enterprise Value-to-Revenue Multiple|Enterprise Value-to-Revenue Ratio ImageneBio Inc IMA|EV/Sales Multiple Shattuck Labs, Inc. STTK|EQ - Enterprise Value-to-Revenue Ratio|connectbiopharm.com (CNTB) - Company Value to Revenue|IMUX (Immunic) - Company Value to Revenue|Atara Biotherapeutics, Inc. - Business Value to Revenue|Enterprise Value-to-Revenue Ratio InflaRx|Company Value to Revenue x4pharma.com (XFOR)|EV/Sales Multiple ACET|Company Value to Revenue Celularity Corp CELU|INmune Bio Inc - Company Value to Revenue|BRNS (Barinthus Bio) - Enterprise Value to Sales Volume|KZR - Enterprise Value-to-Revenue Ratio|Total Company Value-to-Revenue Ratio sabbiotherapeutics.com SABS|Akari Therapeutics PLC (AKTX) - Enterprise Value-to-Revenue Ratio|ENLV - Total Company Value-to-Revenue Ratio|QTTB (Q32 Bio) - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple GeoVax Labs Inc GOVX|Enterprise Value-to-Revenue Ratio Edesa Biotech (EDSA)|Company Value to Revenue iBio IBIO|Carisma Therapeutics Inc - Company Value to Revenue|XTLB - Company Value to Revenue|BOLT - Enterprise Value-to-Revenue Ratio|Business Value to Revenue HCWB (hcwbiologics.com)|APVO: EV/Sales Multiple|aimimmuno.com (AIM) - EV/Sales Multiple|Enterprise Value-to-Revenue Ratio aditxt.com|Company Value to Revenue GRI Bio Corp (GRI)|Enterprise Value-to-Revenue Ratio XORTX Therapeutics Inc. (XRTX)|Company Value to Revenue ReShape Lifesciences HIND|Enterprise Value-to-Revenue Ratio Indaptus Therapeutics, Inc. INDP|EV/Sales Multiple scinai.com SCNI|CalciMedica Inc - EV/Sales Multiple|AFMD - EV/Sales Multiple|ALLK: EV/Sales Multiple|Enterprise Value to Sales Volume HOOK (HOOKIPA Pharma, Inc.)|IGMS (IGM Biosciences) - EV/Sales Multiple|ITOS: Business Value to Revenue|Company Value to Revenue OCEA (Ocean Biomedical)|TCBP: Enterprise Value to Sales Volume|Enterprise Value-to-Revenue Ratio Third Harmonic Bio Inc THRD